Last reviewed · How we verify
Folfox plus Bevacizumab
Folfox plus Bevacizumab is a chemotherapy and angiogenesis inhibitor Small molecule drug developed by Canadian Cancer Trials Group. It is currently in Phase 2 development for Metastatic colorectal cancer.
FOLFOX plus Bevacizumab inhibits angiogenesis and disrupts tumor blood supply through VEGF inhibition, while FOLFOX induces DNA damage and apoptosis in rapidly dividing cells.
Bevacizumab is a vascular endothelial growth factor A inhibitor used in the treatment of metastatic colorectal carcinoma, rectal cancer, and other related conditions. It is administered in combination with FOLFOX, a chemotherapy regimen that includes oxaliplatin, 5-fluorouracil, and leucovorin, to enhance its effectiveness.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Folfox plus Bevacizumab |
|---|---|
| Sponsor | Canadian Cancer Trials Group |
| Drug class | chemotherapy and angiogenesis inhibitor |
| Target | VEGF, DNA synthesis and repair pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), preventing its interaction with VEGF receptors on endothelial cells, thereby inhibiting angiogenesis. FOLFOX, a combination of fluorouracil, leucovorin, and oxaliplatin, works by interfering with DNA synthesis and repair, leading to cell death in rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
Common side effects
- neutropenia
- diarrhea
- fatigue
Key clinical trials
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (PHASE1)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folfox plus Bevacizumab CI brief — competitive landscape report
- Folfox plus Bevacizumab updates RSS · CI watch RSS
- Canadian Cancer Trials Group portfolio CI
Frequently asked questions about Folfox plus Bevacizumab
What is Folfox plus Bevacizumab?
How does Folfox plus Bevacizumab work?
What is Folfox plus Bevacizumab used for?
Who makes Folfox plus Bevacizumab?
What drug class is Folfox plus Bevacizumab in?
What development phase is Folfox plus Bevacizumab in?
What are the side effects of Folfox plus Bevacizumab?
What does Folfox plus Bevacizumab target?
Related
- Drug class: All chemotherapy and angiogenesis inhibitor drugs
- Target: All drugs targeting VEGF, DNA synthesis and repair pathways
- Manufacturer: Canadian Cancer Trials Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing